Hormonal Treatment of Cryptorchidism

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Hormonal treatment of cryptorchidism with a gonadotropic substance from pregnancy urine or with an anterior-pituitary-like substance dates from the early 1930s. Success rates varied from 25 to 100%. Subsequently, human chorionic gonadotropin (hCG) administered intramuscularly came into use. The success rates of several large studies have varied from 25 to 55%. Widely divergent results have, likewise, been reported following the intranasal administration of luteinizing-hormone-releasing hormone (LHRH), the efficacy of which has been investigated in many studies, including placebo-controlled trials. Combined LHRH and hCG treatment schedules have been recently assessed, with equally divergent success rates. The most important factor influencing the rate of success is the testicular position before treatment: the lower the position of the testis before treatment the better the result. The experience with LHRH nasal spray treatment for cryptorchidism in 252 prepubertal boys is presented in this study, including several years follow-up, and the results compared with data reported in the literature.

Related collections

Author and article information

Journal

Journal ID (publisher-id): HRE

Journal ID (doi): 10.1159/issn.0018-5051

Title: Hormone Research in Paediatrics

Publisher: S. Karger AG

ISBN: 978-3-8055-5004-8

ISBN: 978-3-318-01957-5

ISSN (Print): 0018-5051

ISSN (Electronic): 2571-6603

Publication date Subscription-year: 1988

Publication date (Print): 1988

Publication date (Electronic): 02 December 2008

Volume: 30

Issue: 4-5

Pages: 178-186

Affiliations

Division of Endocrinology, Department of Pediatrics, Erasmus University and University Hospital Rotterdam / Sophia Children’s Hospital, The Netherlands

Article

Publisher ID: 181057 Other ID: Horm Res 1988;30:178–186

DOI: 10.1159/000181057

SO-VID: 310aaa42-7ad2-4b7e-b698-6e234ab14f50

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Hormonal Treatment of Cryptorchidism

Read this article at

Abstract

Related collections

Karger: Endocrinology

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 517